1.Drug discovery enters a new era with multi-target intervention strategy.
Chinese journal of integrative medicine 2012;18(7):539-542
In the past century, as medical research has become increasingly precise, it has become clear that the incidence and progression of many diseases involve multiple factors and pathologies; this is particularly true for the degenerative and metabolic diseases facing industrialized societies. At the same time, it becomes increasingly clear that single-target action drugs cannot effectively treat these diseases. Researchers are looking toward the chemical industry as well as traditional herbal medicines to find multi-target interventions. Thus, a new era in drug discovery has begun. Specifically, three approaches have proven effective in seeking multi-target drugs. These are: (1) designing drugs with multiple components; (2) discovering drugs through the study of synergistic compound-compound interactions in medicinal herbs or among chemical drugs and herbal components; and (3) developing drugs to tackle complex multi-component diseases. The authors conclude that there is an increasing need for multi-component remedies to treat the complex chronic diseases afflicting modern populations. Given this situation and the growing body of evidence that these new approaches are effective, multi-target intervention appears to have great potential for discovering, designing, and developing effective new drugs for today's diseases.
Drug Design
;
Drug Discovery
;
trends
;
Drug Synergism
;
Herb-Drug Interactions
;
Humans
;
Molecular Targeted Therapy
;
trends
;
Plants, Medicinal
2.Antiangiogenesis therapy: an update after the first decade.
The Korean Journal of Internal Medicine 2014;29(1):1-11
Angiogenesis is a complex biological phenomenon that forms new blood vessels from the pre-existing vasculature. Aberrant angiogenesis has been implicated in a variety of diseases such as cancer, atherosclerosis, arthritis, obesity, pulmonary hypertension, diabetic retinopathy, and age-related macular degeneration. These conditions collectively affect nearly 10% of the global population. Much effort has focused on identifying new therapeutic agents that inhibit pathological angiogenesis since 1971, when Judah Folkman published the hypothesis that tumor growth is angiogenesis-dependent and that its inhibition may be therapeutic. In 2004, the U.S. Food and Drug Administration approved the first antiangiogenic drug for the treatment of metastatic colon cancer, bevacizumab (Avastin, Genentech). This drug is a humanized monoclonal antibody that neutralizes the vascular endothelial growth factor. It is used in combination with chemotherapy, and its use began the era of antiangiogenesis therapy. Several new therapeutic agents have been added to the list of approved drugs, and clinical trials of new therapeutic options and antiangiogenic agents are ongoing. This review describes the progress made in the first decade of antiangiogenesis therapy, and addresses both validated and possible targets for future drug development.
Angiogenesis Inhibitors/*therapeutic use
;
Humans
;
Macular Degeneration/drug therapy
;
Molecular Targeted Therapy/*trends
;
Neoplasms/drug therapy
;
Neovascularization, Pathologic/metabolism
;
Neovascularization, Physiologic
3.Applications of RNA interference high-throughput screening technology in cancer biology and virology.
Shan GAO ; Chen YANG ; Shan JIANG ; Xiao-Ning XU ; Xin LU ; You-Wen HE ; Annie CHEUNG ; Hui WANG
Protein & Cell 2014;5(11):805-815
RNA interference (RNAi) is an ancient intra-cellular mechanism that regulates gene expression and cell function. Large-scale gene silencing using RNAi high-throughput screening (HTS) has opened an exciting frontier to systematically study gene function in mammalian cells. This approach enables researchers to identify gene function in a given biological context and will provide considerable novel insight. Here, we review RNAi HTS strategies and applications using case studies in cancer biology and virology.
Animals
;
Genetic Predisposition to Disease
;
genetics
;
Humans
;
Molecular Targeted Therapy
;
methods
;
trends
;
Neoplasms
;
genetics
;
therapy
;
RNA Interference
;
Viral Proteins
;
genetics
;
Virus Diseases
;
genetics
;
therapy
;
virology
4.Research progress on the development of the strategies for siRNAs delivery in vivo.
Journal of Biomedical Engineering 2012;29(4):775-779
RNA interference (RNAi) is a powerful endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. Because any protein that causes or contributes to a disease is susceptible to RNAi, the RNAi has high potential for therapeutic treatments. In a clinical setting, however, there are many obstacles to targeted delivery of small interfering RNA (siRNA) in vivo, specificity and stability of the RNAi reagents. In this review, we focus on recent progress in the development of efficient siRNA delivery vehicles to help the application of siRNA to in vivo therapy.
Drug Carriers
;
Gene Transfer Techniques
;
Humans
;
Molecular Targeted Therapy
;
methods
;
trends
;
RNA Interference
;
RNA, Small Interfering
;
administration & dosage
;
genetics
;
metabolism
;
Transfection
5.Tackling the tumor microenvironment: what challenge does it pose to anticancer therapies?
Fei CHEN ; Xinyi QI ; Min QIAN ; Yue DAI ; Yu SUN
Protein & Cell 2014;5(11):816-826
Cancer is a highly aggressive and devastating disease, and impediments to a cure arise not just from cancer itself. Targeted therapies are difficult to achieve since the majority of cancers are more intricate than ever imagined. Mainstream methodologies including chemotherapy and radiotherapy as routine clinical regimens frequently fail, eventually leading to pathologies that are refractory and incurable. One major cause is the gradual to rapid repopulation of surviving cancer cells during intervals of multiple-dose administration. Novel stress-responsive molecular pathways are increasingly unmasked and show promise as emerging targets for advanced strategies that aim at both de novo and acquired resistance. We highlight recent data reporting that treatments particularly those genotoxic can induce highly conserved damage responses in non-cancerous constituents of the tumor microenvironment (TMEN). Master regulators, including but not limited to NF-kB and C/EBP-β, are implicated and their signal cascades culminate in a robust, chronic and genome-wide secretory program, forming an activated TMEN that releases a myriad of soluble factors. The damage-elicited but essentially off target and cell non-autonomous secretory phenotype of host stroma causes adverse consequences, among which is acquired resistance of cancer cells. Harnessing signals arising from the TMEN, a pathophysiological niche frequently damaged by medical interventions, has the potential to promote overall efficacy and improve clinical outcomes provided that appropriate actions are ingeniously integrated into contemporary therapies. Thereby, anticancer regimens should be well tuned to establish an innovative clinical avenue, and such advancement will allow future oncological treatments to be more specific, accurate, thorough and personalized.
Antineoplastic Agents
;
therapeutic use
;
CCAAT-Enhancer-Binding Protein-beta
;
metabolism
;
Humans
;
Models, Biological
;
Molecular Targeted Therapy
;
methods
;
trends
;
NF-kappa B
;
metabolism
;
Neoplasms
;
drug therapy
;
metabolism
;
Precision Medicine
;
methods
;
trends
;
Signal Transduction
;
drug effects
;
Tumor Microenvironment
;
drug effects
6.Drug therapy of overactive bladder - What is coming next?.
Korean Journal of Urology 2015;56(10):673-679
After the approval and introduction of mirabegron, tadalafil, and botulinum toxin A for treatment of lower urinary tract symptoms/overactive bladder, focus of interest has been on their place in therapy versus the previous gold standard, antimuscarinics. However, since these agents also have limitations there has been increasing interest in what is coming next - what is in the pipeline? Despite progress in our knowledge of different factors involved in both peripheral and central modulation of lower urinary tract dysfunction, there are few innovations in the pipe-line. Most developments concern modifications of existing principles (antimuscarinics, beta3-receptor agonists, botulinum toxin A). However, there are several new and old targets/drugs of potential interest for further development, such as the purinergic and cannabinoid systems and the different members of the transient receptor potential channel family. However, even if there seems to be good rationale for further development of these principles, further exploration of their involvement in lower urinary tract function/dysfunction is necessary.
Adrenergic beta-3 Receptor Agonists/therapeutic use
;
Botulinum Toxins, Type A/therapeutic use
;
Drug Therapy, Combination
;
Humans
;
Molecular Targeted Therapy/methods/trends
;
Muscarinic Antagonists/therapeutic use
;
Neuromuscular Agents/therapeutic use
;
Urinary Bladder, Overactive/*drug therapy
7.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.
Experimental & Molecular Medicine 2011;43(10):539-549
To date, more than 30 antibodies have been approved worldwide for therapeutic use. While the monoclonal antibody market is rapidly growing, the clinical use of therapeutic antibodies is mostly limited to treatment of cancers and immunological disorders. Moreover, antibodies against only five targets (TNF-alpha, HER2, CD20, EGFR, and VEGF) account for more than 80 percent of the worldwide market of therapeutic antibodies. The shortage of novel, clinically proven targets has resulted in the development of many distinct therapeutic antibodies against a small number of proven targets, based on the premise that different antibody molecules against the same target antigen have distinct biological and clinical effects from one another. For example, four antibodies against TNF-alpha have been approved by the FDA -- infliximab, adalimumab, golimumab, and certolizumab pegol -- with many more in clinical and preclinical development. The situation is similar for HER2, CD20, EGFR, and VEGF, each having one or more approved antibodies and many more under development. This review discusses the different binding characteristics, mechanisms of action, and biological and clinical activities of multiple monoclonal antibodies against TNF-alpha, HER-2, CD20, and EGFR and provides insights into the development of therapeutic antibodies.
Animals
;
Antibodies, Monoclonal/*pharmacology/therapeutic use
;
Antigens, CD20/immunology
;
Drug Discovery
;
Humans
;
Immune System Diseases/*drug therapy/immunology
;
*Immunotherapy/trends
;
*Molecular Targeted Therapy
;
Neoplasms/*drug therapy/immunology
;
Receptor, Epidermal Growth Factor/immunology
;
Receptor, erbB-2/immunology
;
Tumor Necrosis Factor-alpha/immunology
;
United States
;
United States Food and Drug Administration
;
Vascular Endothelial Growth Factor A/immunology
8.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.
Experimental & Molecular Medicine 2011;43(10):539-549
To date, more than 30 antibodies have been approved worldwide for therapeutic use. While the monoclonal antibody market is rapidly growing, the clinical use of therapeutic antibodies is mostly limited to treatment of cancers and immunological disorders. Moreover, antibodies against only five targets (TNF-alpha, HER2, CD20, EGFR, and VEGF) account for more than 80 percent of the worldwide market of therapeutic antibodies. The shortage of novel, clinically proven targets has resulted in the development of many distinct therapeutic antibodies against a small number of proven targets, based on the premise that different antibody molecules against the same target antigen have distinct biological and clinical effects from one another. For example, four antibodies against TNF-alpha have been approved by the FDA -- infliximab, adalimumab, golimumab, and certolizumab pegol -- with many more in clinical and preclinical development. The situation is similar for HER2, CD20, EGFR, and VEGF, each having one or more approved antibodies and many more under development. This review discusses the different binding characteristics, mechanisms of action, and biological and clinical activities of multiple monoclonal antibodies against TNF-alpha, HER-2, CD20, and EGFR and provides insights into the development of therapeutic antibodies.
Animals
;
Antibodies, Monoclonal/*pharmacology/therapeutic use
;
Antigens, CD20/immunology
;
Drug Discovery
;
Humans
;
Immune System Diseases/*drug therapy/immunology
;
*Immunotherapy/trends
;
*Molecular Targeted Therapy
;
Neoplasms/*drug therapy/immunology
;
Receptor, Epidermal Growth Factor/immunology
;
Receptor, erbB-2/immunology
;
Tumor Necrosis Factor-alpha/immunology
;
United States
;
United States Food and Drug Administration
;
Vascular Endothelial Growth Factor A/immunology